AHR and COVID-19: In this regard, pharmacological inhibition of AhR has been proposed as therapy to increase the host’s antiviral response and consequently reduce viral replication, as well as reducing the mucins expression and limiting lung pathology during COVID-19 (66).In addition, it is important to point out that some metabolites showed differential deregulation in different comparisons.